With ongoing support from licensed clinicians, you'll feel in control again and finally see progress that lasts
GLP-1-RA such as liraglutide [4], semaglutide [5], and the dual agonist tirzepatide [6], activating both the GLP1- and the gastric-inhibitory polypeptide receptor (GIP-R), have been shown to significantly reduce body weight, making them a promising therapeutic option for the treatment of obesity
~$99/mo
Cyano B12 in particular should be avoided, especially in patients with pernicious anemia and/or with high homocysteine
Wang J, Zhou Y, Zhang D, Zhao W, Lu Y, Liu C, et al
Ozempic: Understanding Their Role in Weight Management and Diabetes Control Zepbound and Ozempic have emerged as two leading GLP-1 receptor agonists for weight management and Type 2 diabetes